Michael R. Hayden

Michael R. Hayden, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Ionis Pharmaceuticals Inc, AbCellera Biologics Inc. and 89bio, Inc. We count 20 filings; the first trade dates from 18 May 2021 and the latest from 24 August 2026.

In open-market terms, that means 9 purchases worth €2.6M on one side and 1 sale worth €2.1M on the other. Purchases outweigh sales by €475k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 8 option exercises. 2026 to date brings 4 purchases and no sales.

In size, the median ticket on the buying side is €224k. Measured against the company's value, the median purchase equals 0.011% of market capitalisation, across 4 purchases where it is known. Clusters matter here: 3 out of 9 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 24 August 2026 with an open-market purchase (€488k) in AbCellera Biologics Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.